Role of Functional Genetic Variation in the Dopamine D2 Receptor (DRD2) in Response to Bupropion and Nicotine Replacement Therapy for Tobacco Dependence: Results of Two Randomized Clinical Trials
- 10 August 2005
- journal article
- research article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 31 (1) , 231-242
- https://doi.org/10.1038/sj.npp.1300861
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Treating Tobacco Dependence: State of the Science and New DirectionsJournal of Clinical Oncology, 2005
- Translating emerging research on the genetics of smoking into clinical practice: Ethical and social considerationsNicotine & Tobacco Research, 2004
- The effects of the DRD2 polymorphism on smoking cessation and negative affect: Evidence for a pharmacogenetic effect on moodNicotine & Tobacco Research, 2004
- Effects of quitting smoking on EEG activation and attention last for more than 31 days and are more severe with stress, dependence, DRD2 A1 allele, and depressive traitsNicotine & Tobacco Research, 2004
- Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trialBMJ, 2004
- Measures of abstinence in clinical trials: issues and recommendationsNicotine & Tobacco Research, 2003
- Applying genetic approaches to the treatment of nicotine dependenceOncogene, 2002
- Smoking withdrawal dynamics in unaided quitters.Journal of Abnormal Psychology, 2000
- The Fagerström Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance QuestionnaireBritish Journal of Addiction, 1991
- The CES-D ScaleApplied Psychological Measurement, 1977